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Background: Due to the hypervascular nature of glioblastoma (GBM), antiangiogenic 
treatments, such as vatalanib, have been added as an adjuvant to control angiogenesis and 
tumor growth. However, evidence of progressive tumor growth and resistance to antiangiogenic 
treatment has been observed. To counter the unwanted effect of vatalanib on GBM growth, 
we have added a new agent known as N-hydroxy-N′-(4-butyl-2 methylphenyl)formamidine 
(HET0016), which is a selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) 
synthesis. The aims of the studies were to determine 1) whether the addition of HET0016 
can attenuate the unwanted effect of vatalanib on tumor growth and 2) whether the treatment 
schedule would have a crucial impact on controlling GBM.
Methods: U251 human glioma cells (4×105) were implanted orthotopically. Two different 
treatment schedules were investigated. Treatment starting on day 8 (8–21 days treatment) of the 
tumor implantation was to mimic treatment following detection of tumor, where tumor would 
have hypoxic microenvironment and well-developed neovascularization. Drug treatment starting 
on the same day of tumor implantation (0–21 days treatment) was to mimic cases following 
radiation therapy or surgery. There were four different treatment groups: vehicle, vatalanib 
(oral treatment 50 mg/kg/d), HET0016 (intraperitoneal treatment 10 mg/kg/d), and combined 
(vatalanib and HET0016). Following scheduled treatments, all animals underwent magnetic 
resonance imaging on day 22, followed by euthanasia. Brain specimens were equally divided 
for immunohistochemistry and protein array analysis.
Results: Our results demonstrated a trend that HET0016, alone or in combination with vatalanib, 
is capable of controlling the tumor growth compared with that of vatalanib alone, indicating 
attenuation of the unwanted effect of vatalanib. When both vatalanib and HET0016 were admin-
istered together on the day of the tumor implantation (0–21 days treatment), tumor volume, tumor 
blood volume, permeability, extravascular and extracellular space volume, tumor cell prolifera-
tion, and cell migration were decreased compared with that of the vehicle-treated group.
Conclusion: HET0016 is capable of controlling tumor growth and migration, but these effects 
are dependent on the timing of drug administration. The addition of HET0016 to vatalanib may 
attenuate the unwanted effect of vatalanib.
Keywords: magnetic resonance imaging, glioblastoma, antiangiogenic treatments, HET0016, 
vascular parameters, protein array
Introduction
Glioblastoma (GBM) is a hypervascular malignant brain tumor with poor prognosis, 
even with the best combination of treatments.1 The hypervascular nature of GBM has 
made antiangiogenic treatment (AAT) a popular adjuvant to inhibit angiogenesis and 
tumor growth.2–5 However, clinical results indicate transient beneficial effects of AAT 
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(measured in weeks or months), followed by tumor restora-
tion and progression.6 Presently, a number of compounds that 
are intended to control the abnormal angiogenesis are being 
studied.7,8 Agents, such as vatalanib (PTK787, a vascular 
endothelial growth factor receptor 2 [VEGFR2] tyrosine kinase 
inhibitor), cediranib, sunitinib, and so forth, which play a role 
in interfering with the VEGFR signaling transduction pathways 
have shown varying degrees of clinical success with relapse 
or recurrence of tumors,4,9 thus demonstrating the develop-
ment of tumor resistance to AAT.10 In some cases, inhibiting 
angiogenesis has also shown an increase in lymphatic and 
metastatic activities.11 Bevacizumab is a ligand-based mono-
clonal antibody against VEGF, unlike all of the other receptor-
based therapies. According to the recently published studies, 
bevacizumab in clinical settings showed adverse effect and did 
not improve the patient’s survival.12,13 In GBMs, AAT actually 
induced a phenotypic change from a single-cell infiltration to 
a cluster of cells migrating along normal blood vessels.8,14–16 
The invasive growth pattern may imply a qualitative change in 
tumor response after AAT. To avoid further potential therapeu-
tic failures, these mechanisms of resistance to antiangiogenic 
therapy in clinical settings need to be better understood.
An important feature of AAT is the disrupted tumor 
vasculature and associated marked hypoxia, which may be 
one of the important reasons for AAT resistance. Following 
marked hypoxia, a chain of mechanisms are triggered which, 
we believe, establish some alternative pathways for angiogen-
esis via various tumor secreted factors, such as basic fibroblast 
growth factor (bFGF), stromal cell-derived factor-1 alpha 
(SDF-1α), protein–regulated upon activation, normal T-cell 
expressed and secreted (RANTES) or CCL5, VEGF, and 
many other proangiogenic factors.4,16–19 Another potentially 
distinct resistant mechanism may also be the recruitment of 
endothelial progenitor cells (EPCs), as well as proangiogenic 
monocytes from bone marrow to the tumor site.20 Hypoxia 
creates a permissive condition for the recruitment of a hetero-
geneous population of monocytic bone marrow-derived cells, 
which promotes angiogenesis and tumor growth.21,22
To create a clinically relevant treatment, it is impor-
tant to control both tumor cell proliferation and neovas-
cularization. N-Hydroxy-N′-(4-butyl-2-methylphenyl) 
formamidine (HET0016), a highly selective inhibitor of 
20-hydroxyeicosatetraenoic acid (20-HETE) synthesis, 
has been reported to inhibit the enzymatic activity of the 
CYP4A and CYP4F families.23 The significant findings of 
treatment with HET0016 are the ability to inhibit several 
growth factors, as well as angiogenesis in an U251-induced 
cornea angiogenesis model.24 Further studies with HET0016 
identified some of the agent’s hallmarks in controlling tum-
origenesis via multiple pathways. The agent controlled the 
growth of tumor cells, inhibited the effect of growth factors 
on tumor angiogenesis and vasculogenesis, and inhibited 
the angiogenic effects of EPCs.25,26 A possible mechanism 
of action of HET0016 in relation to growth factor pathways 
is shown in Figure 1. There has not been any report showing 
the effectiveness of HET0016 in controlling GBM resistance 
to AAT, especially vatalanib. Therefore, we hypothesize that 
HET0016 has the potential to control alternative angiogenic 
pathways induced by vatalanib in GBM and control the 
resistant of GBM to vatalanib treatment.
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Figure 1 Possible mode of action of heT0016 in relation to growth factor pathways.
Notes: (A) Treatment with vatalanib causes decrease in expression of VegFr2 but increases the expression of hiF-1a and VegF, which will cause increased neovascularization 
and tumor growth. (B) When heT0016 alone is used, VegF expression is decreased through different signaling pathways, which will cause decreased neovascularization and tumor 
growth. (C) When heT0016 and vatalanib are used together some of the effects of vatalanib (increase VegF, increased neovascularization and tumor growth) can be attenuated.
Abbreviations: heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; VegFr, vascular endothelial growth factor receptor; 20-heTe, 20-hydroxyeicosatetraenoic 
acid; hiF-1α, hypoxia-inducible factor-1α; egFr, epidermal growth factor receptor; erK1/2, extracellular signal-regulated protein kinases 1 and 2.
OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1207
antitumor effect of heT0016
Unlike normal cerebral vasculature, hypervascular 
regions of the tumor are typically permeable to contrast 
agents (CAs) and thus can be detected by magnetic resonance 
imaging (MRI) or computed tomography modalities. These 
studies allow for the analysis of tumor size, perfusion, tumor 
blood volume, permeability, and extravascular and extracel-
lular space volume fraction. The parameters provided by 
MRI help identify changes in tumor vascular physiology 
after AAT. In particular, investigators have utilized dynamic 
contrast-enhanced (DCE)-MRI to generate maps of vascular 
permeability (forward volumetric transfer constant, Ktrans), 
tumor plasma volume (v
p
), backward transfer constant (K
ep
), 
and interstitial space volume fraction (v
e
) in GBM patients.27 
These parameters may allow for a better understanding 
of the physiological characteristics of the regional tumor 
environment and vascularity.
The purposes of the study were to determine whether the 
timing of treatment using either HET0016 and vatalanib alone 
or in combination would have a crucial impact on controlling 
the growth of GBM, whether addition of HET0016 would 
prevent the drug resistance of GBM to vatalanib, and whether 
the parametric analysis of MRI could detect significant 
changes in the tumors following different treatments.
Materials and methods
ethical statement
All animal experiments were approved and performed based 
on the National Institutes of Health guidelines and by the 
Institutional Animal Care and User Committee of Henry Ford 
Health Systems and Georgia Regents University. The study 
protocols was approved by the Ethics Committees of Henry 
Ford Health Systems and Georgia Regents University.
animal model
Nude rats (RNU nu/nu) (Charles River Laboratories, Inc., 
Frederick, MD, USA), ∼150–170 g in weight, were included 
in this study. An orthotopic glioma model was established by 
injecting human glioma U251 cells (4×105), suspended in 5 µL 
of serum-free Roswell Park Memorial Institute (RPMI) 1640, 
into the right hemisphere of the brain. The suspended cells 
were injected at 3 mm to the right and 1 mm anterior to bregma 
according to the previously published methods.16,19,28,29
Drug treatments and schedule
Establishing a tumor model that mimics clinical scenarios 
has become a very important aspect in preclinical research. 
Animals were randomly assigned to two treatment schedules. 
The first sets of animals were designated to mimic a clinical 
scenario, in which treatment was started after diagnosing 
an established tumor in a hypoxic microenvironment and 
prominent neovascularization. We waited for 7 days after 
implantation, allowing the tumor to grow ∼3 mm in size, 
and started the treatment on day 8, 5 days/wk until day 21. 
The second sets of animals were designated to mimic clinical 
postsurgical cases, in which a small number of cells may 
remain outside of the surgical field, resulting in a recurrent 
tumor. Animals in this group were treated from day 0, along 
with tumor implantation, 5 days/wk until day 21. In both 
treatment schedules, the animals were further divided into 
the following four treatment groups: vehicle, vatalanib alone 
(50 mg/kg/d orally), HET0016 alone (10 mg/kg/d, intrap-
eritoneally), and vatalanib plus HET0016. The doses of the 
drugs were selected according to our own publications, as 
well as other reports.30,31 All the animals underwent MRI on 
day 22, followed by euthanasia.
Each of the postmortem subgroups were divided for either 
protein array or immunohistochemistry (IHC). There were a 
total of 75 animals. Out of 75, five animals were excluded due 
to failure of MRI acquisition or early death of the animals. 
MRI vascular parametric analysis was not possible in seven 
animals due to faulty intravascular injection; however, these 
animals were used for analysis of either IHC or protein 
array. There were 14 animals in the vehicle (control) group 
(nine animals for 8–21 days and five animals for 0–21 days), 
19 animals for vatalanib treatments (eleven animals for 
8–21 days and eight animals for 0–21 days), 19 animals for 
HET0016 treatments (eleven animals for 8–21 days and eight 
animals for 0–21 days), and 18 animals for combined vata-
lanib and HET0016 treatments (ten animals for 8–21 days 
and eight animals for 0–21 days).
in vivo Mri
As noted earlier, all animals underwent MRI on day 22, 
according to their treatment schedules. Animals were 
anesthetized with 2% isoflurane and steadily supplied with 
oxygen while secured to a customized cradle. All studies were 
performed in a Varian (now Agilent Technologies, Santa 
Clara, CA, USA), 7 T, 20 cm bore system with a DirectDrive 
spectrometer and console. The maximum strength and rise 
time of gradient were 250 mT/m and 120 µs, respectively. 
All MRI image sets were acquired with a 32×32 mm2 field 
of view. Animals were first located with the tumor center 
corresponding to the magnet center by a triplanar fast low 
angle shot sequence. Subsequent scans were acquired using 
T1-weighted (pre- and postcontrast), T2-weighted, dual 
gradient echo with a variable flip angle, and dual gradi-
ent echo DCE-MRI scans to estimate Ktrans, K
ep
, v
p
, and 
v
e
. The pre- and postcontrast T1-weighted images were 
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acquired in a spin-echo T1-weighted multislice sequence 
(repetition time [TR]/echo time [TE] =800/15.68 ms, 
128×96 matrix, 27 slices [0.4 mm thick and gap 0.1 mm], 
and number of summed acquisitions [NEX] =4). Spin-echo 
T2-weighted images were obtained using standard two-
dimensional Fourier transformation multislice (27 slices, 
0.4 mm thick and gap 0.1 mm) multiecho sequence: TE/
TR =20, 40, 60, 80/3,000, 128×96 matrix, and NEX =2. 
Prior to the DCE-MRI sequence, and immediately after, two 
Driven Equilibrium Single Pulse Observation of T1 (DES-
POT1) sequences32 were run, using a dual-echo SPGRE 
sequence (the “mgems” sequence in the Agilent VnmrJ 
library) allowing a voxel-by-voxel estimation of T1 in the 
tissue pre- and post-CA administration. DESPOT1 sequence 
parameters are as follows: flip angles =3°, 5°, 7°, 12°, 15°, 
25°, 45°, and 70°, matrix 128×64, seven 1.8 mm slices on 
2 mm centers, and TE/TR =2.0, 4.0/80 ms. The DCE-MRI 
sequence was a dual-echo SPGRE (2GE) sequence with the 
same geometry and timing as the DESPOT1 sequence but 
with a fixed flip angle of 35° and an acquisition of 150 image 
sets at 5.13 s intervals for a total run time of ∼12.8 minutes. 
At image 15 of the 2GE sequence, a bolus injection of the 
CA (Magnevist; Bayer Healthcare Pharmaceuticals, Wayne, 
NJ, USA), 0.25 mmol/kg at undiluted concentration, no 
flush, was performed by hand push, followed by a slight 
drawback.
Tumor volume analysis
Postcontrast T1-weighted images were used to determine 
the tumor volume. Two investigators, blinded to the various 
treatment groups, determined the volume by drawing irregu-
lar region of interests (ROIs) for all slices containing tumor. 
To calculate the exact volume, investigators summed up the 
number of slices and multiplied it by the slice thickness.
Kinetic analysis
The model equation
Since the basic approach to the pharmacokinetics of DCE 
studies has been previously published,27,33,34 we proceeded to 
the model equation associated with the full standard model 
used for parametric estimates33 as follows:
 ∆ ∆ ∆R t K e R v R t
t
k tt
1 10
( ) ( ) ( )( )= +− −∫trans p p 1pep dτ τ τ  (1)
where R
1p
 is the longitudinal relaxation rate of all protons in 
the blood plasma, R
1t
 is the longitudinal relaxation rate of 
all protons in the tissue, Ktrans is the unidirectional volume 
transfer rate of the indicator from plasma across the vascular 
endothelium and blood–brain barrier into the interstitial 
space, k
ep
 is the transfer rate constant from the interstitial 
compartment to the vascular compartment, and v
p
 is the 
fractional volume of the CA’s vascular distribution space, 
usually thought to be the plasma distribution space. The 
plasma fractional volume and the blood fractional volume 
are related via the following relationship: (v
b
 = v
p
/[1 - Hct]), 
where Hct is the average hematocrit in the vessels of the 
voxel and v
b
 is blood fraction volume.
ΔR1 calculation
Under experimental conditions, ie, using a dual-echo gradient 
echo sequence (the “mgems” sequence in the Agilent VnmrJ 
library), and assuming that the flip angle is known across the 
brain of the rodent, an estimate of the time trace of ΔR
1
 can 
be calculated from the following equation:
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where S(t) is the signal intensity at time t, M
0
 is the equilibrium 
magnetization of the protons, θ is the flip angle, TR is the 
repetition time between pulses, TE is the echo time (the time 
between the center of the excitation pulse and the readout gra-
dient), and R*
2
(t) is the transverse relaxation rate. Equation 2 
can be solved for R
1
(t):
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(3)
numerical methods – processing
Using data from the DESPOT1 studies performed before 
and after the 2GE DCE-MRI study, voxel-by-voxel maps of 
T1 pre and postcontrast were generated by nonlinear least 
squares fitting.27 Given the T1 maps and dynamic 2GE data 
before and following the CA injection, the concentration–
time curve of the CA was approximated by the calculated 
ΔR
1
 variation in time, using Equation 3. As mentioned in 
previous publications,33–35 a scaled radiological input function 
was used as the arterial input function in all studies. A global 
starting point was selected, usually one or two time points 
after the arrival of the indicator in the vasculature, and the 
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next 105 data points (∼9 minutes) were fitted by minimizing 
the sum of squared error. A model selection paradigm was 
used27,33 to ensure the stability in the parametric estimates.
In model 3 regions, the regions where the full model of 
Equation 1 could be fitted, Ktrans, K
ep
, v
p
, and v
e
, of the whole 
tumors (control and treated), were determined by drawing 
irregular ROIs on ImageJ (NIH, Bethesda, MD, USA). Mul-
tiple investigators, blinded to both groups, determined the 
vascular parameters from the whole tumor. For the whole 
tumor, an irregular ROI was drawn.
Protein extraction from glioma
Euthanized animals were perfused with ice cold ×1 
phosphate-buffered saline. Brain tissues were collected and 
snap frozen immediately for preservation. For protein extrac-
tion, both hemispheres were separated, and surrounding tissue 
around the tumor was carefully removed. Next, investigators 
carefully cut the sections into small pieces and pulverized 
the samples. The entire brain tissue processing was done on 
dry ice to avoid degradation of brain proteins. The collected 
tissues of the tumor were lysed using RayBiotech protocol 
(RayBiotech, Norcross, GA, USA). Bovine serum albumin 
provided by BioRad Protein Assay (Bio-Rad Laboratories 
Inc., Hercules, CA, USA) was used as a standard to measure 
total protein concentration.
Protein analysis
The following proangiogenic factors were selected and 
analyzed based on positive signal intensity: angiogenin, 
angiostatin, angiopoietin-1, angiopoietin-2, G-CSF, platelet-
derived growth factor AA (PDGF-AA), platelet-derived 
growth factor receptor A (PDGF-Ra), RANTES, bFGF, 
epidermal growth factor (EGF), EFGR, IGF-1, MMP-9, 
SDF-1α, Tie-1, Tie-2, VEGF-A, VEGF-C, VEGFR2, and 
VEGFR3. The membranes were specific for human cytok-
ines, based on a chemiluminescent-labeling quantitative 
methodology. The developed membranes were imaged using 
a Multispectral Imaging System (Carestream). Later, the 
acquired images were analyzed measuring the signal intensity 
(pixel density) using ImageJ software. All signals emitted 
from the membrane were normalized to the positive control 
spots of the corresponding membrane.
histopathology
Animals were euthanized and perfused by intracardiac 
injection of 100 mL ice cold ×1 phosphate-buffered saline, 
followed by 3% paraformaldehyde solution. All collected 
brain specimens were fixed in a solution containing 
3% paraformaldehyde and 3% sucrose. Tissue sections 
were processed via either frozen or paraffin blocks for 
standard histology staining procedures. Our focus being 
on angiogenesis, proliferation, and human-specific marker 
to determine the position and number of invasive cells, we 
selected appropriate antibodies to target specific sites in the 
glioma. Von-Willebrand factor was used as the marker (Dako 
Denmark A/S, Glostrup, Denmark) for angiogenesis, Ki-67 
(EMD Millipore, Billerica, MA, USA) was used to detect 
the proliferation, and major histocompatibility complex 
class 1 (MHC-1; now human leukocyte antigen A [HLA-A]; 
Abcam, [San Francisco, CA, USA]) was used for human-
specific marker.
evaluation of microvessel density
Von-Willebrand factor IHC helped to detect the microvessel 
in the tumor environment for determining angiogenesis.36–38 
After tissue samples were stained, slides were microphoto-
graphed in five different areas, in which highly concentrated 
tube-like formations were observed. Images were taken at ×40 
magnification with the AmScope microscope. Microvessel 
density (MVD) was determined by ImageJ using the color-
thresholding image analysis method, in which highly dense 
positively stained vessels were highlighted and measured. 
A minimum of two investigators separately conducted the 
analysis to determine reproducibility and alleviate a biased 
estimation.
evaluation of proliferation
Ki-67 IHC helped to detect the proliferation status of tumor 
cells. Slides were stained and microphotographed in five 
different areas (center, left, right, upper, and lower). In 
each image taken, all cells were counted (total cells), brown 
(positive for Ki-67) and blue (hematoxylin positive) cells. 
The proliferation rate was calculated by dividing the total 
number of brown cells (positive for Ki-67) by total number 
of cell (brown and blue cells).
evaluation of invasive tumor cells 
(Mhc-1)
MHC-1 IHC helped to detect cells that expressed human 
markers (ie, human U251 glioma cells in rat brain) and to 
determine the distance between the invasive MHC-1-positive 
cells from the primary tumor mass. Images were taken at 
low magnification, ×4 and ×10, to view the invasive cells 
away from the periphery of the primary tumor mass. The 
tumor periphery was confirmed on high magnification before 
all measurements. An irregular line was drawn at the most 
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peripheral part of the tumor, which showed continuation to 
the primary tumor mass. Any MHC-1-positive cells away 
from the drawn line were considered invasive cells. A per-
pendicular line was drawn from the invasive tumor cells or 
tumor foci (center of the foci) to the drawn line at the tumor 
periphery, and the distance was noted. Distance from the 
migrated individual cell or distal tumor foci to the periphery 
of the primary tumor mass was determined, and the aver-
age values were calculated. The analysis was done using 
the software supplied by the vendor (ToupView Software; 
ToupTek Photonics Co. Ltd, Irvine, CA, USA).16 After many 
data points were collected, all distances were averaged and 
represented in micrometer (µm).
statistical analysis
Comparisons between drug- and vehicle-treated groups were 
done by using a one-way analysis of variance with protected 
least significant difference (PLSD) post hoc test. All results 
were expressed as mean ± standard error of mean. A P-value 
,0.05 was considered significant in all analysis.
Results
combination of heT0016 and vatalanib 
attenuated the refractory tumor growth 
observed with vatalanib alone
Significant differences in tumor volume were observed 
among the treatment groups or between the two treatment 
schedules (Figure 2). When the treatment started on day 8 
following implantation of tumor cells, vatalanib showed 
significantly (P=0.0368) increased tumor volume, as shown 
by MRI on day 22 (Figure 2, upper and lower panels). The 
effect of vatalanib on tumor growth is similar to that of our 
previously published data.16,19 The addition of HET0016 to 
vatalanib attenuated the refractory tumor growth observed 
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Figure 2 Tumor volume.
Notes: representative postcontrast T1-weighted images show enhanced tumor from different groups of animals. Tumor volumes were measured by drawing appropriate 
ROIs on each postcontrasted T1-weighted slice per animal. All of the slices were summed and multiplied by slice thickness. Semiquantitative analysis shows significantly 
increased tumor volume in groups of animals that received vatalanib from day 8 and continued for 2 weeks. *Significant difference from vehicle-treated animals (P,0.05).
Abbreviations: rOi, region of interest; heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.
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with vatalanib alone when the treatment started on day 8. 
When the treatment started on the day of the tumor implanta-
tion, HET0016 and combined treatment showed decreased 
tumor volume, although a statistically significant difference 
was not achieved.
heT0016, in combination with vatalanib, 
altered the permeability transfer constant 
and but not the other vascular parameters
The results from our vascular parametric analysis relayed 
valuable information about the vascular kinetics in the 
tumor environment (Figure 3A and B). The first parameter 
we checked was the v
p
. There were no differences in v
p
 
values among the groups of animals when the treatment 
started on day 8 (8–21 days) (Figure 3A). The second 
parameter we analyzed was the vascular forward perme-
ability transfer constant (Ktrans), in which we noted a sig-
nificant difference between vehicle- and combination of 
HET0016 plus vatalanib-treated groups (P=0.0232), when 
animals were treated 8–21 days (Figure 3A). The other 
two parameters, backward transfer constant (K
ep
) and 
interstitial space volume (v
e
), were analyzed and proved no 
significant differences among the groups in both treatment 
schedules. v
p
 was significantly different among the groups 
of animals that were treated early (0–21 days). There were 
significant differences observed between vehicle vs vata-
lanib (P=0.0071) and vehicle vs HET0016 (P=0.0065), 
when animals were treated from 0 to 21 days (Figure 3B). 
Although the v
p
 was lower when both drugs were used in 
combination, significant differences were not achieved 
between the vehicle- and the combination of HET0016 plus 
vatalanib-treated groups.
heT0016 treatment in developed 
tumor increased the expression of 
proangiogenic factors
The 20 proangiogenic factors/receptors were analyzed from 
the tumor lysate to determine which factors/receptors were 
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modulated during the treatments. Figure 4 and Table 1 
summarize the values of different factors following treatments 
in two different treatment schedules, and significant dif-
ferences among the groups. There were six growth factors 
(G-CSF, PDGF-Ra, PDGF-AA, bFGF, EGF, and EGFR) 
upregulated when animals were treated from 8 to 21 days 
with HET0016 compared with that of corresponding vehicle-
treated animals. Along with the six growth factors, angio-
genin (P=0.0173), angiostatin (P=0.0075), and RANTES 
(P=0.0010) were also upregulated when compared with 
vehicle. However, there were no significant differences 
observed for any of the factors between vehicle vs vatalanib 
and vehicle vs combined treatment groups when the treatment 
started on day 8 (8–21 days).
Interestingly, the 0–21 days treatment group did not 
show similar trends between vehicle vs HET0016 com-
pared with that of the 8–21 days treatment group. Tie-1 
(P=0.0264) and VEGFR3 (P=0.0401) were the only two 
factors that showed upregulation in the 0–21 days treatment 
group.
Treatments did not alter MVD
MVD analysis was performed to observe the neovasculariza-
tion in the tumor following different treatments. There were 
no significant differences in either of the treatment schedules 
or among the treatment groups (Figure 5). Comparing across 
both treatment schedules, we observed no change in the 
density of vessels.
combined treatments of heT0016 and 
vatalanib decreased proliferation of cells 
in tumors
Ki-67 staining was performed to observe the proliferation 
of the tumor cells in different drug-treated animals. The bar 
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Figure 3 Vascular parameters.
Notes: representative images of different vascular parameters and semiquantitative analysis in groups of animals that received treatment on day 8 (A) and on day 0 (B). 
Vascular parametric maps were created from dynamic contrast-enhanced magnetic resonance imaging. Vascular parametric values were measured by drawing appropriate 
ROIs on representative images per animal. On the one hand, early treatment with vatalanib and HET0016 (started on day 0) caused significant decrease in tumor plasma 
volume. On the other hand, late treatment (started on day 8) with the combination of HET0016 and vatalanib caused significant increase in permeability (Ktrans). *Significant 
difference from vehicle-treated animals (P,0.05 to ,0.01).
Abbreviations: rOi, region of interest; heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.
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Figure 4 Protein array analysis.
Notes: custom-designed protein array membrane was used to determine the expression of different growth factors and cytokines. The protein array membranes were 
imaged using luminescence imager, and each spot with signal intensity was measured using a circular rOi. The rOi size was kept consistent from array to array and spot to 
spot, making the variation subtle. Protein array values normalized to corresponding positive control show differential expressions of proangiogenic and growth factors based 
on the schedules of treatments and the added drugs. Late treatment with HET0016 caused significantly increased expression of many factors.
Abbreviations: rOi, region of interest; heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; g-csF, granulocyte colony-stimulating factor; PDgF-ra, platelet-
derived growth factor receptor A; PDGF-AA, platelet-derived growth factor AA; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; sDF-1α, stromal cell-derived factor-1 alpha; VegFr, vascular endothelial growth factor receptor.
graphs show (Figure 6) no statistically significant differences 
among the groups that were treated from 8 to 21 days, but in 
treatment schedule 0–21 days, combination of HET0016 plus 
vatalanib-treated group shows significantly lower (P=0.015) 
proliferation compared with that of other groups, including 
the vehicle.
heT0016 treatment decreased migration 
of tumor cells
MHC-1 staining was performed to observe human glioma 
tumor cells deep into the rat brain to determine the migration 
or invasion of tumor cells. All of the drugs caused significantly 
decreased migration of human cells from the primary tumor 
mass to deeper part of surrounding rat brain when compared 
with that of vehicle-treated animals in the 8–21 days 
treatment schedule (vehicle vs vatalanib, P,0.0001; 
vehicle vs HET0016, P,0.0001; and vehicle vs combined, 
P,0.0001) (Figure 7). However, the results were different 
when the treatment started on day 0 (0–21 days). Treatment 
with HET0016 alone did not decrease the migration of tumor 
cells, whereas treatment with vatalanib alone or vatalanib plus 
HET0016 caused significantly decreased migration of tumor 
cells compared with that of vehicle-treated group.
Discussion
The results of our studies demonstrated that the effect of 
vatalanib and HET0016 on glioma is dependent on the timing 
of the administration of the drug, with respect to the stages 
of tumor development. We also demonstrated that HET0016, 
a selective competitive inhibitor of the synthesis of 20-HETE, 
in combination with vatalanib, is capable of controlling the 
tumor growth, tumor cell proliferation, cell migration, and dif-
ferent vascular parameters (although not significantly for all). 
20-HETE, a metabolite of arachidonic acid (AA) produced 
OncoTargets and Therapy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1214
shankar et al
by the CYP4A and CYP4F enzyme families, may act as a 
second messenger for the vasoactive and mitogenic responses 
of some growth factors, including angiotensin II, norepineph-
rine, endothelin, vasopressin, serotonin, and EGF, and can be 
an important mediator of VEGF, inducing angiogenesis.24,39,40 
VEGFR2 tyrosine kinase inhibitor, vatalanib, increased 
the tumor volume and permeability when the drug was 
administered in a developed tumor (days 8–21 treatment). 
The current findings are in parallel with our previously 
published reports.16,19 To our surprise, permeability was sig-
nificantly increased when vatalanib was added to HET0016. 
The mechanisms of increasing permeability following 
vatalanib treatment are not straightforward. Our previous 
publications indicated paradoxical expression of hypoxia-
inducible factor-1α (HIF-1α) at the peripheral part of the 
tumor following vatalanib treatment, which caused increased 
production of SDF-1α and VEGF. In the same publications, 
we indicated dilated vessels at the peripheral part of the 
tumors.19 SDF-1α is also known to mobilize bone marrow-
derived progenitor cells, which induce neovascularization by 
vasculogenesis.20,41,42 Our recent data also proved increased 
mobilization and accumulation of bone marrow progenitor 
cells in the tumors following vatalanib treatments.43 Any 
type of neovessels (both angiogenesis and vasculogenesis) 
would be permeable to the administered MRI contrast agent. 
However, it is not clear why combined treatment (addition 
of HET0016) would make blood vessels more permeable. 
HET0016 is shown to normalize blood vessels in the tumor 
when administered early in the tumor development31 and 
also inhibit the VEGF-mediated proliferation and migration 
of EPCs.26 Because of the developed tumor, HET0016 might 
not have worked as expected, and the addition of vatalanib 
enhanced neovascularization. However, when both vatalanib 
and HET0016 were administered together on the day of tumor 
implantation (0–21 days treatment), tumor volume, tumor 
blood volume, permeability, and extravascular and extracel-
lular space volume were decreased when compared with the 
corresponding vehicle-treated group. The results indicate the 
importance of early treatment as soon as the tumor is resected 
without being delayed for the appearance of recurrent tumor. 
It should be mentioned that our postsurgical mimic may not 
reflect the exact clinical scenario, where leftover cells are 
already embedded in the surrounding microenvironment with 
established circulation. However, based on our findings, early 
treatment would decrease tumor invasion.
There has been no report showing the effects of HET0016 
on the expression level of different growth and proangiogenic 
factors in GBM. Investigators have shown increased level of 
Table 1 effect of treatments on protein expression pattern of proangiogenic factors/receptors in glioblastoma tumor
Proangiogenic factors Treatment 8–21 days Treatment 0–21 days
Vehicle vs HET0016 Vehicle vs vatalanib 
(PTK787)
Vehicle vs HET0016 Vehicle vs combined
angiogenin P=0.0173 ns ns ns
angiostatin P=0.0075 ns ns ns
angiopoietin-1 ns ns ns P=0.0414
angiopoietin-2 ns ns ns ns
g-csF P=0.0271 ns ns ns
PDgF-ra P=0.0222 ns ns ns
PDgF-aa P=0.0025 ns ns ns
ranTes P=0.0010 ns ns ns
bFgF P=0.0118 ns ns ns
egF P=0.0062 ns ns ns
egFr P=0.0005 ns ns ns
igF-1 ns ns ns ns
MMP-9 ns ns ns ns
sDF-1α ns ns ns ns
Tie-1 ns ns P=0.0264 ns
Tie-2 ns ns ns ns
VegF-a ns ns ns ns
VegF-c ns ns ns ns
VegFr2 ns ns ns ns
VegFr3 ns P=0.0202 P=0.0401 P=0.0176
Abbreviations: heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; NS, not significant; G-CSF, granulocyte colony-stimulating factor; PDGF-Ra, platelet-derived 
growth factor receptor A; PDGF-AA, platelet-derived growth factor AA; bFGF, basic fibroblast growth factor; EGF, epidermal growth factor; EGFR, epidermal growth factor 
receptor; sDF-1α, stromal cell-derived factor-1 alpha; VegFr, vascular endothelial growth factor receptor.
OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1215
antitumor effect of heT0016
VEGF and MMP-9 in tumors that overexpress cytochrome 
P450 ω-hydroxylase, which converts AA to 20-HETE that 
induces angiogenic responses in vivo and in vitro,44,45 and 
HET0016 inhibits the synthesis of 20-HETE. HET0016 is 
shown to inhibit the angiogenic response to EGF, VEGF, and 
bFGF.24,46 Given the complexity of the angiogenic process, 
we evaluated several proangiogenic factors to determine their 
behaviors during the treatment. Current consensus is that 
VEGF is the most important proangiogenic factor, and it can 
be modulated and stimulated by several other growth factors. 
VEGF expression by tumors is upregulated by hypoxia and 
is often elevated near the areas of tumor necrosis or at the 
periphery.19 Hypoxia activates an HIF-1α-binding sequence 
in the VEGF promoter, which leads to VEGF messenger 
RNA transcription and stability. Guo et al47 showed that 
20-HETE first caused an increase in VEGF, which in turn 
causes the upregulation of HIF-1α. The resulting activation of 
HIF-1α in these cancers leads to the transcriptional induction, 
not only of VEGF and VEGFRs but also of endothelin-1, 
angiopoietins, and angiopoietin receptors (Tie-1 and -2). 
HET0016 treatment (8–21 days schedule) increased the 
expression of PDGF-Ra, PDGF-AA, bFGF, EGF, and EGFR, 
which are well-known proangiogenic factors. In our previous 
study on a breast cancer model, we noticed two different 
phenomena.48 With a short-term treatment with HET0016, 
all these aforementioned factors were downregulated, which 
was also seen in our in vitro studies (data not shown). The 
findings are also supported by Guo et al, who had shown 
that short-term treatment with HET0016 inhibited EGFR in 
U251 cells.46 However, when the treatment was continued 
for a longer period of time, there was an upregulation of 
these factors in the breast cancer.48 In the current studies, 
we also noticed two phenomena. When the treatment was 
started on day 8, these factors were upregulated, whereas 
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Figure 5 Mean vascular density.
Notes: Five different, highly dense vascular areas were photomicrographed within the tumor mass. each image was thresholded in imageJ, making sure only the vWF-positive 
staining was highlighted and positive areas were noted. Analysis of mean vascular density and histochemical images show no significant increased or decreased vascular density 
for following early or late treatments. ihc images were taken at ×40 magnification.
Abbreviations: vWF, Von-Willebrand factor; ihc, immunohistochemistry; heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.
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when the treatment started on day 0 (on the day of tumor 
implantation), we did not notice any upregulation of these 
factors. We believe that the changes are due to different 
tumor cells (breast cancer vs glioma), treatment schedules, 
and activation of compensatory downstream EGFR signaling 
mechanisms for survival of tumor. Similar expressions were 
not observed when HET0016 was combined with vatalanib. 
Although these factors were increased, there was no increase 
in angiogenic response in treated tumors as indicated by 
nonsignificant changes in MVD in all treatment groups. 
The observed paradoxical effects indicate the importance 
of timing of treatment in tumors using HET0016 alone or in 
combination of vatalanib. Chronic inhibition of 20-HETE 
signaling decreased EGFR phosphorylation in mouse cystic 
kidneys, suggesting that 20-HETE has the ability of coupling 
and transactivation of EGFR.49 Similar effects were also 
found in U251 glioma cells, where 20-HETE inhibition 
by HET0016 reduced an EGFR activation, and subsequent 
proliferation stimulated by EGF.46,47 These findings are 
in accordance with our results when treatment started on 
day 0. On the other hand, preceding studies have indicated 
exacerbated signaling of multiple members of the EGFR 
family, often causing uncontrolled proliferation of cancer 
cells, possibly justifying the reason for high levels of EGF 
and EGFR in tumors when the treatment started on day 8 (in 
a developed tumor) in our study.50
Unlike previous studies, our results did not indicate 
decreased proliferation capacity of the tumor cells in either 
of the treatment schedules or in any of the treatment groups 
except the combined early treatment (day 0). We believe, due 
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Figure 6 Proliferative capacity.
Notes: histochemical images and analysis of proliferative capacity of the tumor cells following different treatments. Five different regions with higher expression of ki67 
were taken within the tumor mass, and brown and blue cells were counted in total. The total number of browns cells (Ki-67 stained) was divided by the total number of 
cells (blue and brown cells). Combined HET0016 and vatalanib treatment started on day 0 caused significantly lower proliferative cells in the tumor. IHC images were taken 
at ×40 magnification. *Significant difference from vehicle-treated animals (P,0.05).
Abbreviations: heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; ihc, immunohistochemistry; Vata, vatalanib.
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to low plasma availability and single-dose administration, it 
yielded no changes, when compared with previous studies, in 
which two injections per day were administered. When com-
paring the invasion of the tumor cells following treatments, 
all animals in late treatment groups (days 8–21) showed 
significant decrease in cell migration/invasion in comparison 
to corresponding vehicle-treated animals. On the other hand, 
decreased cell migration in vatalanib- and combined-treated 
animals was observed only in the early treatment groups. 
These differential effects can be explained as follows: 
1) day 8 treatment has already developed tumor with an estab-
lished microenvironment and 2) day 0 treatment has no estab-
lished microenvironment, except tumor cell. The decrease 
in migration suggests that the treatment somehow decreased 
the invasiveness by affecting the microenvironment (stromal 
cells) at the invasive front (periphery of tumor), indicating 
that inhibitors have more effect on the microenvironment 
rather than the tumor cells. Different chemokine/growth fac-
tors and receptors are implicated for tumor cells to become 
migratory or invasive phenotypes.51,52 One of the complexes 
is SDF-1/CXCR4, which increases the binding of tumor cells 
to extracellular matrix through α5β3 integrin activation.52,53 
Recently, investigators have demonstrated that α5β1 integrin 
binds to activate c-Met, which initiates Src/FAK signaling 
and promotes migration in ovarian cancer cells.54 Integrin 
EGFR macromolecular signaling complexes are also impli-
cated for the changes in phenotype from normal epithelial 
to migratory cell types in breast cancer.55,56 Other growth 
factors, such as EGF and IGF-1 have also been shown to 
increase migratory capacity of different malignant cells.51 
Wild-Bode et al have demonstrated that activity of MMP-2 
and MMP-9 is the best predictor of glioma cell migration 
in an in vitro study.57 Other investigators have also pointed 
out the importance of MMPs in cell migration and invasion 
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Figure 7 invasion of tumor cells.
Notes: Migration of cell was determined by drawing a perpendicular line from the migrated cells to the periphery of the primary tumor mass. When the distances the 
tumor cells migrated away from the central tumor mass were determined, there were significantly decreased invasion following late treatments with vatalanib, HET0016, and 
combination of HET0016 plus vatalanib. Both vatalanib and combined treatments started on day 0 (early treatment) caused significantly decreased invasion of tumor cells. The 
following symbols show the comparison among different groups. *Significant difference from vehicle-treated animals (P,0.0001). #Significant difference between vatalanib vs 
heT0016 alone or combined treatments (P,0.0001). @Significant difference between HET0016 vs vatalanib or combined treatments (P,0.0001).
Abbreviations: heT0016, N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine; Vata, vatalanib.
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in glioma.58 We also reported increased migration of glioma 
cells following sublethal irradiation, which caused increased 
expression of CD44 and MMP-2.59 Despite increased EGF 
and EGFR expression (protein array data) with HET0016, 
there was no increased cell invasion/migration away from the 
primary tumor mass, which could be due to the attenuation of 
MMP-9. In both early and late HET0016 treatment groups, 
MMP-9 was lower (borderline significant differences) com-
pared with vehicle-treated animals.
Conclusion
In summary, our results demonstrated that HET0016, a 
selective competitive inhibitor of the synthesis of 20-HETE, 
alone or in combination of VEGFR2 tyrosine kinase inhibitor 
(vatalanib), is capable of attenuating the tumor growth, 
tumor cell proliferation, cell migration, and different vascu-
lar parameters. However, all of these observations are con-
tingent upon respective tumor developmental stages, timing, 
and selection of the appropriate drug administered.
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